Palvella Therapeutics, Inc. Common Stock

PVLA XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

Short interest (Jul 15)

15.2%

Net Short (Jul 27 ): 0.1%

Borrow Fee

0.44%

↓ 40.3%

Available Shares

60K

↑ 1797.9%

Price Chart

Company Overview

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001583648

Asset Type: CS

Market Data

Market Cap: $1,979,455,900

Employees: 29

Status: Active

Short Interest

Current Borrow Fee 0.44%

Range: 0.44% - 0.44%

Available Shares 60K

Range: 40K - 80K

Recent Changes

Fee Change: ↓ 10.5%

Available Change: ↓ 98.7%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime